72761-60-5

Basic information

• Product Name: 9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride
• Synonyms: 9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride;9-Azabicyclo(3.3.1)non-3-one Hydrochloride
• CAS NO: 72761-60-5
• Molecular Formula: C₈H₁₃NO*ClH
• Molecular Weight: 175.66
• Product Categories: Amines and Anilines;Carbonyl Compounds
• Mol File: 72761-60-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 277.2 °C at 760 mmHg
• Flash Point: 121.4 °C
• Appearance: /
• Vapor Pressure: 0.00353mmHg at 25°C
• CAS DataBase Reference: 9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride(72761-60-5)
• EPA Substance Registry System: 9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride(72761-60-5)

Safety Data

• Hazardous Substances Data: 72761-60-5(Hazardous Substances Data)

Usage

General Description

9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride is an organic compound that is commonly used in chemical research or as a building block for the synthesis of various pharmaceuticals and other fine chemicals. It is a bicyclic compound with a nitrogen atom incorporated into the ring structure, and the hydrochloride salt form is often utilized for increased stability and solubility. 9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride has potential applications in the pharmaceutical industry, particularly in the development of new drugs targeting the central nervous system due to its structural similarity to certain neurotransmitters. Additionally, it may also be used as a reagent in organic chemistry reactions for the preparation of complex molecules.

InChI:InChI=1/C8H13NO.ClH/c10-8-4-6-2-1-3-7(5-8)9-6;/h6-7,9H,1-5H2;1H

Upstream product

• 512822-27-4 tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 552-70-5 pseudopelletierine 
• 1336-21-6 ammonium hydroxide 
• 149381-95-3 9-(2,2,2-trichlorocarbethoxy)-9-azabicyclo[3.3.1]nonan-3-one 

Downstream Products

• 512822-27-4 tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 934180-37-7 tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 926658-81-3 9-[(4-chlorophenyl)sulfonyl]-9-azabicyclo[3.3.1]nonan-3-one 
• 180406-53-5 methyl (2R,6S)-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine-6-ethanoate 
• 225089-42-9 methyl (2S,6R)-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine-6-ethanoate 
• 180580-54-5 (1S,5R)-N-(p-tolylsulfonyl)-3-(trimethylsilyloxy)-9-azabicyclo<3.3.1>non-2-ene 
• 180406-45-5 (1R,5S)-N-(p-tolylsulfonyl)-3-(trimethylsilyloxy)-9-azabicyclo<3.3.1>non-2-ene 
• 180406-54-6 (2R,6S)-6-formylmethyl-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine 
• 225089-43-0 (2S,6R)-6-formylmethyl-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine 
• 501-02-0 (-)-pinidine 
• 180406-57-9 N-p-tolylsulfonyl-9-azabicyclo<3.3.1>nonan-3-one 

Relevant articles and documents

Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators

The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and l-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis'

BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE

The invention provides N-cyclic sulfonamido compounds and salts of Formula (I): wherein A is as described in the specification and R1 and R2combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula (I) are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula (I).